Celgene gets MS blockbuster-in-waiting ozanimod back on trackRegulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple Share XCelgene gets MS blockbuster-in-waiting ozanimod back on trackhttps://pharmaphorum.com/news/celgene-gets-ms-blockbuster-in-waiting-ozanimod-back-on-track/
German Merck shows new data backing BTK drug evobrutinib in MSGermany’s Merck KGaA has announced new mid-stage data that it says support further studies into its BTK inhibitor Share XGerman Merck shows new data backing BTK drug evobrutinib in MShttps://pharmaphorum.com/news/german-merck-shows-new-data-backing-btk-drug-evobrutinib-in-ms/
Addressing MS’ two-tier healthcare system is about ‘social justice’NICE has reversed its decision not to approve a new drug that offers hope to thousands of people Share XAddressing MS’ two-tier healthcare system is about ‘social justice’https://pharmaphorum.com/views-analysis-patients/ms-two-tier-healthcare-system/
Biogen’s R&D strategy fails to impress after Alzheimer’s trial flopThe dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s Share XBiogen’s R&D strategy fails to impress after Alzheimer’s trial flophttps://pharmaphorum.com/news/biogens-rd-strategy-fails-to-impress-after-alzheimers-trial-flop/
European regulator restricts use of Sanofi MS drug LemtradaThe European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of Share XEuropean regulator restricts use of Sanofi MS drug Lemtradahttps://pharmaphorum.com/news/european-regulator-restricts-use-of-sanofi-ms-drug-lemtrada/
Merck’s oral MS drug finally gets FDA okayMerck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after Share XMerck’s oral MS drug finally gets FDA okayhttps://pharmaphorum.com/news/mercks-oral-ms-drug-finally-gets-fda-okay/
MS drug market heats up as FDA backs Novartis’ new pillThe FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a Share XMS drug market heats up as FDA backs Novartis’ new pillhttps://pharmaphorum.com/news/ms-drug-market-heats-up-as-fda-backs-novartis-new-pill/
Celgene refiles potential MS blockbuster ozanimod with FDACelgene has filed its highly anticipated oral MS drug ozanimod with the US regulator, more than a year Share XCelgene refiles potential MS blockbuster ozanimod with FDAhttps://pharmaphorum.com/news/celgene-refiles-potential-ms-blockbuster-ozanimod-with-fda/
Merck KGaA admits to ‘challenging’ 2018, as currencies hit salesGermany’s Merck KGaA has described 2018 as a “challenging” year, which saw profits hit by currency headwinds and Share XMerck KGaA admits to ‘challenging’ 2018, as currencies hit saleshttps://pharmaphorum.com/news/merck-kgaa-admits-to-challenging-2018-as-currencies-hit-sales/
